Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT06109415

Cohort 1 (TSA) of: A Multi-surgery Assessment of ZYNRELEF (HTX-011)

Conditions: Postoperative Pain, Total Shoulder Arthroplasty, Multimodal Analgesia

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE4
Enrollment: 30
Sponsor: Heron Therapeutics

Location: Woodland International Research Group, LLC Little Rock Arkansas

Summary

Cohort 1 (subjects undergoing total shoulder arthroplasty, TSA) of a Phase 4, randomized, blinded, active-controlled, multicohort study to evaluate HTX-011 compared with bupivacaine HCl in subjects undergoing different surgical procedures. See also the separate record for the master study protocol (NCT05109312).

Eligibility Criteria

Inclusion Criteria: * Has American Society of Anesthesiologists (ASA) Physical Status of I, II, or III. * Is scheduled to undergo a unilateral Total Shoulder Arthroplasty. Exclusion Criteria: * Is undergoing a revision surgery. * Has a known or suspected history of hypersensitivity or clinically significant idiosyncratic reaction to bupivacaine (or other local anesthetics), NSAIDs, acetaminophen, oxycodone, morphine, or hydromorphone. * History of severe allergic reaction to aspirin or other NSAIDs, or known history of severe gastrointestinal adverse reactions associated with NSAID use. * Has taken meloxicam within 10 days prior to the scheduled surgery, or any NSAID within 24 hours prior to the scheduled surgery, with the exception of subjects on low-dose (≤100 mg) daily acetylsalicylic acid for cardioprotection. * Opioid use for most days within the last 3 months prior to Screening in the opinion of the Investigator. * Has been administered immediate-release bupivacaine HCl within 5 days prior to the scheduled surgery, or a modified-release bupivacaine product within 14 days prior to the scheduled surgery. * Has initiated treatment with any of the following medications within 1 month prior to study drug administration: selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, gabapentin, pregabalin, duloxetine, or cyclooxygenase-2 inhibitors. * Has been administered systemic steroids within 5 half-lives or 10 days prior to the scheduled surgery (whichever is longer). * Has a known or suspected history of drug abuse, a positive drug screen (except for cannabinoids) on the day of surgery, or a history of alcohol abuse within the past 5 years. * Suspected or confirmed active coronavirus disease 2019 (COVID-19) infection. * Had a malignancy in the last year, with the exception of nonmetastatic basal cell or squamous cell carcinoma of the skin or localized carcinoma in situ of the cervix. * Has undergone 3 or more surgeries within 12 months, other than for diagnostic procedures (eg, colonoscopy). * Has a body mass index (BMI) \>40 kg/m2.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT06109415). StuddyBuddy aggregates publicly available trial information.